Key Small Cap Updates Strong Monthly Performers Calzada (CZD) – market cap $29m (up 70% for month) CZD’s wholly owned subsidiary PolyNovo Biomaterials reported positive results from its fi rst NovoSorb human clinical trial. The trial involved a prospective, randomized, controlled study of NovoSorb foam as the wound dressing for Topical Negative Pressure (TNP) therapy in the treatment of chronic and complex pressure sores (decubitus ulcers). A total of 18 patients and 20 pressure sores were treated - 10 with NovoSorb foam and 10 with the current “gold standard” dressing (GranuFoam). The NovoSorb dressings met the primary outcome of the study which was to demonstrate the safety of the foam, and its effi cacy as a TNP interface. Importantly, NovoSorb also demonstrated a reduction in dressing fragmentation, risk of infection, trauma on dressing removal (diffi culty and bleeding), and undesirable dressing retention in the wound over GranuFoam.
And this from Urethane Update under Patents, unable to access the detail, however dated May 17th and nice to see patents for product developments still be applied for.
SYSTEMS >> BIOMATERIALS >> BIODEGRADABLE POLYMERS Biodegradable polyurethane/urea compositions The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing wi... Published On: May 17, 2013 Company: PolyNovo Biomaterials Limited
Have a good weekend
CZD Price at posting:
7.3¢ Sentiment: Buy Disclosure: Held
